U.S., June 11 -- ClinicalTrials.gov registry received information related to the study (NCT07014319) titled 'Phase II Trial of Maribavir for CMV in Patients With Lymphoid Malignancy on Bispecific Antibodies' on May 21.
Brief Summary: This is an open-label, single arm, multicenter study to evaluate the feasibility of maribavir treatment in multiple myeloma and lymphoma patients undergoing bispecific antibody treatment and experiencing treatment emergent CMV events
Study Start Date: Sept. 01, 2025
Study Type: INTERVENTIONAL
Condition:
Cytomegalovirus (CMV)
Intervention:
DRUG: Maribavir
Participants will receive maribavir 400 mg twice daily starting from Week 1 and continuing until clearance of CMV. CMV clearance is defined as either a...